drugset / Trial / NCT05524857
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this research is to study the safety and tolerability and to establish the maximum tolerated dose (MTD) of the combination of two drugs, fedratinib and decitabine, for the treatment of advanced-phase MPNs.
Timeline
- Start
- 2022-01-28
- Primary completion
- 2024-04-09
- Completion
- 2024-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Fedratinib | Small molecule | 300 mg | Oral |
| Subject | Fedratinib | Small molecule | 400 mg | Oral |